1. Filip I.
   Can low-burden HIV pre-exposure prophylaxis become affordable in low- and middle-income countries?
   AIDS 2026.
   


2. Lujintanon S, Rebeiro PF, Althoff KN, Jones JL, et al.
   Retention in care: is it still a clinically useful indicator for monitoring long-term engagement in HIV care in the treat-all era?
   AIDS 2026.
   


3. Zhao S, McCallum S, Awwad A, Castle PE, et al.
   Cancer incidence and risk factors among people with HIV in REPRIEVE.
   AIDS 2026.
   


4. Daher J, Koberssy Z, Moussallem N, Wu Q, et al.
   Effects of semaglutide on subclinical cardiovascular health in people with HIV.
   AIDS 2026.
   


5. Arnold MJ, Spacek L, Bush KNV, Waring AA, et al.
   A Synopsis of the 2025 U.S. Department of Veterans Affairs and U.S. Department of Defense Clinical Practice Guideline for Lipid Management for Cardiovascular Disease Risk Reduction.
   Ann Intern Med 2026.
   


6. Clark DC, Banerjee J, Baden R, Coffey C, et al.
   Health Economic Analysis of the AMBITION Protocol for Human Immunodeficiency Virus-Associated Cryptococcal Meningitis in the United States.
   Clin Infect Dis 2026.
   


7. Lawrence DS, Jarvis JN.
   When the Evidence Aligns: Single-Dose Liposomal Amphotericin B for Cryptococcal Meningitis in High-Income Settings.
   Clin Infect Dis 2026.
   


8. Lucas A, Steiner L, Genade L, Pattamukkil A, et al.
   Trends in Tuberculosis Preventive Therapy Prescribing Among People Living with HIV in South Africa, 2005-2022.
   J Acquir Immune Defic Syndr 2026.
   


9. Ferraris CM, D'Avanzo PA, Schiavoni NF, Knox J, et al.
   Longitudinal Performance of Self-Reported ART Adherence Compared With Tenofovir Diphosphate in Dried Blood Spots in South Africa.
   J Acquir Immune Defic Syndr 2026.
   


10. Muller JG, Ngasala BE, Sanders EA, Yang G, et al.
    Parasite strain turnover and mosquito infectivity in untreated subpatent malaria.
    J Infect Dis 2026.
    


11. Bwakura-Dangarembizi M, Chappell E, Kityo C, Anena DL, et al.
    Switch to injectable cabotegravir-rilpivirine given every 8 weeks in adolescents living with HIV with virological suppression in sub-Saharan Africa (LATA): a randomised, open-label, multicentre, 96-week non-inferiority trial.
    Lancet 2026.
    


12. Fumagalli MJ, Kaczynska A, Allombert M, Lopes-Ribeiro A, et al.
    Broadly neutralizing antibodies in adult males living with HIV undergoing analytical treatment interruption: secondary and exploratory outcomes of the phase II randomized controlled RIO trial.
    Nat Med 2026.
    


13. Mgbako O.
    Honoring the Legacy of the HIV Epidemic.
    N Engl J Med 2026;395:1048-1049.
    


14. Chaphekar D, Rajakumar RC, Persaud AT, Fernandes C, et al.
    Applying intravirion staining to discern extracellular vesicles from viruses with flow virometry.
    Virology 2026;625:111081.
    


15. Stoicescu C, Mohd Salleh NA, Giacomello C, Faye RAY, et al.
    The war on drugs is a war on women.
    BMJ 2026;394:e100686.
    

Display articles in

• Abstract format